Next report date
Report period
H1 2024
EPS estimate
—
Revenue estimate
—
−1.1200EUR
−28.34 MEUR
−3.62 MEUR
19.19 M
About VIVORYON THERAPEUTICS N.V.
Sector
Industry
CEO
Frank T. Weber
Website
Headquarters
Halle
Founded
2001
ISIN
NL00150002Q7
FIGI
BBG007BB73P6
Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its product pipeline includes PQ912, PBD-C06, and PQ1565. The company was founded by Hans-Ulrich Demuth and Konrad Glund on July 25, 1997 and is headquartered in Halle, Germany.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on MUN exchange VIVORYON THERAPEUTICS stocks are traded under the ticker 05Y.
VIVORYON THERAPEUTICS is going to release the next earnings report on Aug 29, 2024. Keep track of upcoming events with our Earnings Calendar.
Yes, you can track VIVORYON THERAPEUTICS financials in yearly and quarterly reports right on TradingView.
05Y net income for the last quarter is −17.63 M EUR, while the quarter before that showed −10.72 M EUR of net income which accounts for −64.48% change. Track more VIVORYON THERAPEUTICS financial stats to get the full picture.
No, 05Y doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 05Y shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VIVORYON THERAPEUTICS stock right from TradingView charts — choose your broker and connect to your account.
We've gathered analysts' opinions on VIVORYON THERAPEUTICS future price: according to them, 05Y price has a max estimate of 64.00 EUR and a min estimate of 0.70 EUR. Read a more detailed VIVORYON THERAPEUTICS forecast: see what analysts think of VIVORYON THERAPEUTICS and suggest that you do with its stocks.